Comparison of Aliskiren/Hydrochlorothiazide Combination Therapy and Amlodipine Monotherapy in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus

Journal of Clinical Hypertension

Volumn 13, Issue 12, 2011, Pages 889-897

  Townsend, Raymond R ^a   Forker, Alan D ^b   Bhosekar, Vaishali ^c   Yadao, Anthony ^d   Keefe, Deborah L ^d  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b St Luke's Lipid and Diabetes Research Center   (United States)

^c NOVARTIS HEALTHCARE PVT LTD   (India)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC DYSFUNCTION; SYSTOLIC HYPERTENSION; UPPER RESPIRATORY TRACT INFECTION;

AMIDES; AMLODIPINE; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FUMARATES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; RENIN; SYSTOLE;

EID: 83055186450     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2011.00552.x     Document Type: Article

References (41)

1. Wong ND, Lopez VA, L'Italien G, et al. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004. Arch Intern Med. 2007;167:2431-2436.
2. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121-2158.
3. Bakris GL, Sowers JR. ASH position paper: treatment of hypertension in patients with diabetes-an update. J Clin Hypertens (Greenwich). 2008;10:707-713. discussion 714-715.
4. Weycker D, Nichols GA, O'Keeffe-Rosetti M, et al. Risk-factor clustering and cardiovascular disease risk in hypertensive patients. Am J Hypertens. 2007;20:599-607.
5. Collins AJ, Vassalotti JA, Wang C, et al. Who should be targeted for CKD screening? Impact of diabetes, hypertension, and cardiovascular disease Am J Kidney Dis. 2009;53:S71-S77.
6. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36:646-661.
7. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-1252.
8. Malik S, Lopez V, Chen R, et al. Undertreatment of cardiovascular risk factors among persons with diabetes in the United States. Diabetes Res Clin Pract. 2007;77:126-133.
9. Ong KL, Cheung BM, Wong LY, et al. Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004. Ann Epidemiol. 2008;18:222-229.
10. Suh DC, Kim CM, Choi IS, et al. Trends in blood pressure control and treatment among type 2 diabetes with comorbid hypertension in the United States: 1988-2004. J Hypertens. 2009;27:1908-1916.
11. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
12. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
13. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
14. Hanes DS, Nahar A, Weir MR. The tissue renin-angiotensin-aldosterone system in diabetes mellitus. Curr Hypertens Rep. 2004;6:98-105.
15. Giacchetti G, Sechi LA, Rilli S, et al. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab. 2005;16:120-126.
16. Price DA, Porter LE, Gordon M, et al. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol. 1999;10:2382-2391.
17. Azizi M, Webb R, Nussberger J, et al. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens. 2006;24:243-256.
18. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:2588-2605.
19. Chen CH, Nevo E, Fetics B, et al. Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure. Validation of generalized transfer function. Circulation. 1997;95:1827-1836.
20. O'Rourke MF, Seward JB. Central arterial pressure and arterial pressure pulse: new views entering the second century after Korotkov. Mayo Clin Proc. 2006;81:1057-1068.
21. Agabiti-Rosei E, Mancia G, O'Rourke MF, et al. Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension. 2007;50:154-160.
22. Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2007;8:190-198.
23. Yarows SA, Oparil S, Patel AB, et al. Initial use of the aliskiren/valsartan combination is more effective than either component monotherapy in hypertensive patients with diabetes. J Clin Hypertens. 2010;12:A49 PO-72.
24. Ferdinand K, Weitzman R, Lee J, et al. Efficacy and safety of direct renin inhibition in combination with calcium-channel blockade and hydrochlorothiazide in minorities with stage 2 hypertension. Hypertension. 2010;56:e85-P145.
25. Ferdinand K, Pool JL, Weitzman R, et al. Effects of aliskiren + hydrochlorothiazide versus amlodipine on peripheral and central blood pressure in African American patients with stage 2 hypertension. J Hypertens. 2010;28:e18.
26. Brown MJ, McInnes GT, Papst CC, et al. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet. 2011;377:312-320.
27. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433-2446.
28. Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant. 2009;24:1663-1671.
29. McGill JB. Improving microvascular outcomes in patients with diabetes through management of hypertension. Postgrad Med. 2009;121:89-101.
30. Reboldi G, Gentile G, Angeli F, et al. Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. Vasc Health Risk Manag. 2009;5:411-427.
31. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-1010.
32. Weber MA, Giles TD. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy? Rev Cardiovasc Med. 2006;7:45-54.
33. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007;25:217-226.
34. Black HR, Kribben A, Aguirre Palacios F, et al. Aliskiren alone or in combination with hydrochlorothiazide in patients with the lower ranges of stage 2 hypertension: the ACQUIRE randomized, double-blind study. J Clin Hypertens. 2010;12:917-926.
35. Menard J, Azizi M. The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren. J Hypertens. 2007;25:1775-1782.
36. Krum H, Massie B, Abraham WT, et al. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Eur J Heart Fail. 2011;13:107-114.
37. Gheorghiade M, Albaghdadi M, Zannad F, et al. Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). Eur J Heart Fail. 2011;13:100-106.
38. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703-713.
39. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33. UK Prospective Diabetes Study Group. Lancet. 1998;352:837-853.
40. ACCORD Study Group, Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-1585.
41. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61-68.